Status:
NOT_YET_RECRUITING
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
Lead Sponsor:
University Hospital, Lille
Conditions:
Breast Cancer
Liver Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs ...
Detailed Description
Part 1 sequential multi-gene sequencing (Simple NGS), * Multi-gene DNA sequencing (43 genes panel corresponding to the most frequently targeted molecular alterations) * And if no contributive: Part ...
Eligibility Criteria
Inclusion
- \- Age \>18 years.
- Advanced disease status ("unresectable" or "metastatic").
- Patient included either at the time of diagnostic investigation or during first line of treatment.
- Good general conditions, still compatible with a therapeutic proposal, WHO 0-1.
- The following tumour sites, with poor prognosis and for which ESCAT II/IV treatment targets can be found according to ESMO:
- pancreatic adenocarcinoma
- hepatocellular carcinomas,
- triple negative breast cancer.
- Tumour tissue a priori available in sufficient quantity: at least one biopsy from a visceral metastatic site or surgical specimen (if available) for eligible cancers.
- Patient covered by a social sercurity scheme
Exclusion
- \- General condition WHO \>1 and/or nutritional status not compatible with a therapeutic proposal
- Limiting systemic cardiovascular, renal, bronchopulmonary or endocrinological comorbidities with the initiation of a therapeutic proposal
- Active infection or active chronic disease (diabetes, liver dysfunction, immune disease) making the patient's condition incompatible with a therapeutic proposal.
- A priori unavailable, in insufficient quantity or of suboptimal quality tumour material.
- Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign consent.
Key Trial Info
Start Date :
May 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 9 2029
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT06958224
Start Date
May 10 2025
End Date
January 9 2029
Last Update
May 6 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.